Last reviewed · How we verify
BMS-790052
BMS-790052 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune responses.
BMS-790052 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck cancer.
At a glance
| Generic name | BMS-790052 |
|---|---|
| Also known as | Daclatasvir (DCV) |
| Sponsor | Bristol-Myers Squibb |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By blocking the PD-1 receptor, BMS-790052 allows T cells to recognize and attack cancer cells more effectively. This mechanism is thought to be responsible for its anti-tumor activity. BMS-790052 is designed to be used in combination with other cancer treatments to enhance their effectiveness.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck cancer
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia (NA)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
- Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases
- An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (PHASE2)
- Antiviral Agents Against COVID-19 Infection (PHASE2, PHASE3)
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (PHASE4)
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-790052 CI brief — competitive landscape report
- BMS-790052 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI